Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A (NCT03932201)

🧪 Interventions in This Study

• Damoctocog alfa pegol (Jivi, Bay94-9027) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (29 Sites)

Showing the first 25 of 29 sites.

• South Alabama Medical Science Foundation — Mobile, Alabama
• Banner MD Anderson Cancer Center — Phoenix, Arizona
• University California Davis — Davis, California
• Orthopaedic Hospital DBA Orthopaedic Institute for Children — Los Angeles, California
• The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders — Orange, California
• University of Colorado Hemophilia and Thrombosis Center — Aurora, Colorado
• Georgetown University — Washington D.C., District of Columbia
• Tulane University — New Orleans, Louisiana
• Regents of University of Minnesota — Minneapolis, Minnesota
• East Carolina University - Brody School of Medicine — Greenville, North Carolina
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,
• Many locations — Multiple Locations,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hemophilia A

• Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle" — Little Rock, Arkansas
• Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A — Los Angeles, California
• Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A — Milwaukee, Wisconsin
• A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A — Gainesville, Florida
• A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A — Gilbert, Arizona
• Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults — Mountain View, California

Explore by condition: All Hemophilia A clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.